Pineal Region Neoplasm
NCI Definition: Neoplasms that are located in the pineal gland. These neoplasms arise either from pineal parenchymal cells (pineocytes), as do pineocytomas and the more aggressive pineoblastomas, or from other cell types, as do pineal astrocytic tumors (notably pilocytic astrocytomas) and germ cell tumors. Clinical symptoms include neuro-ophthalmologic dysfunction, changes in mental status, dysfunction of the brain stem, and hypothalamic-based endocrine abnormalities. 
Pineal region neoplasms most frequently harbor alterations in DICER1, ATRX, EPHB1, CDK12, and CBL .
DICER1 Mutation, EPHB1 V205E, EPHB1 Mutation, CDK12 P1091S, and CDK12 Mutation are the most common alterations in pineal region neoplasm .
There is 1 clinical trial for pineal region neoplasm, of which 1 is open and 0 are completed or closed. Of the trial that contains pineal region neoplasm as an inclusion criterion, 1 is phase 2 (1 open).
Nivolumab is the most common intervention in pineal region neoplasm clinical trials.
Significant Genes in Pineal Region Neoplasm
H3F3A is an inclusion eligibility criterion in 1 clinical trial for pineal region neoplasm, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and pineal region neoplasm as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.